Elsevier to Address Key Regulatory and Literature Management Challenges at Risk Management and Pharmacovigilance Summit

Delegation to present on the optimization of pharmacovigilance workflows for improved compliance

New York, September 15, 2015

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that it is speaking at the 2nd Annual Risk Management and Pharmacovigilance Summit, which begins today in Vienna, Austria. A four-strong delegation from Elsevier, which is also a silver sponsor of the Summit, will be attending from the 15th to the 17th of September.

James Dunstan, Regional Manager Pharmaceutical Biotech Corporate Sales, Elsevier, will be presenting to Summit attendees on how to optimize literature management throughout the entire pharmacovigilance workflow, on the 16th September at 16:30 CET. James will discuss industry trends and key developments in pharmacovigilance literature monitoring, as well as outlining key challenges that Elsevier has helped customers face.

“With the amount of literature being published increasing significantly every year, Pharmacovigilance professionals are facing an enormous literature management challenge,” said James. “This Summit provides Elsevier with the opportunity to discuss how pharmacovigilance workflows can be better optimized, with risk monitoring based upon more comprehensive data. We greatly value this time with our colleagues across the industry, because we’re able to listen, gather feedback and ultimately improve our solutions to lead the way in advancing science, technology and health.”

In addition to attending the Summit, Elsevier will also be sponsoring four of the ‘Pharmacovigilance Days’ events across Europe in the coming months, as it continues to help companies both overcome the obstacles that huge amounts of scientific literature pose, and maintain compliance.

Elsevier offers several solutions and services for improved pharmacovigilance and risk monitoring, including Embase, the world’s most comprehensive biomedical literature database for institutions and individuals; PharmaPendium, a fully searchable database of drug approval documents and extracted data to inform critical drug development decisions; and QUOSA, an end-to-end scientific literature management tool for life science professionals, used by companies such as Sanofi. Elsevier is also currently developing and expanding its solutions and services offered in this space.

The 2nd Annual Risk Management and Pharmacovigilance Summit is held at the Hotel de France in Vienna, Austria, from the 15th-17th September.

---

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Christopher Capot
Director, Corporate Relations
Elsevier
+1 917 704 5174
c.capot@elsevier.com